Jaap Fransen

List of Publications by Year
in descending order

55 papers	4,001 citations	218677 26 h-index	155660 55 g-index
56 all docs	56 docs citations	56 times ranked	5368 citing authors

#	Article	IF	Citations
1	Younger age and female gender are determinants of underestimated cardiovascular risk in rheumatoid arthritis patients: a prospective cohort study. Arthritis Research and Therapy, 2021, 23, 2.	3.5	8
2	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. Journal of Rheumatology, 2021, 48, jrheum.201594.	2.0	6
3	Prediction of organ involvement and survival in systemic sclerosis patients in the first 5â€‰years from diagnosis. Journal of Scleroderma and Related Disorders, 2020, 5, 57-65.	1.7	8
4	Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. Pharmacogenomics, 2019, 20, 85-93.	1.3	13
5	Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study. Clinical Rheumatology, 2019, 38, 1385-1391.	2.2	39
6	Efficacy of a Web-Based Self-Management Enhancing Program for Patients with Rheumatoid Arthritis: Explorative Randomized Controlled Trial. Journal of Medical Internet Research, 2019, 21, e12463.	4.3	27
7	Crystal-proven Gout and Characteristic Gout Severity Factors Are Associated with Cardiovascular Disease. Journal of Rheumatology, 2018, 45, 858-863.	2.0	33
8	Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial. Trials, 2018, 19, 449.	1.6	14
9	Is fatigue a disease-specific or generic symptom in chronic medical conditions?. Health Psychology, 2018, 37, 530-543.	1.6	79
10	The effect of curriculum sample selection for medical school. Advances in Health Sciences Education, 2017, 22, 43-56.	3.3	20
11	Costâ€Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2017, 69, 175-182.	3.4	8
12	IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis. Scientific Reports, 2017, 7, 41629.	3.3	20
13	Performance of the 2015 ACR-EULAR classification criteria for gout in a primary care population presenting with monoarthritis. Rheumatology, 2017, 56, 1335-1341.	1.9	12
14	Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial. Annals of the Rheumatic Diseases, 2017, 76, 1716-1722.	0.9	39
15	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.9	794
16	Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study. Journal of Rheumatology, 2017, 44, 1325-1330.	2.0	21
17	Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. Arthritis and Rheumatology, 2017, 69, 429-438.	5.6	93
18	Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. Trials, 2017, 18, 403.	1.6	18

#	ARTICLE	IF	CITATIONS
19	Performance of classification criteria for gout in early and established disease. Annals of the Rheumatic Diseases, 2016, 75, 178-182.	0.9	36
20	Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. Arthritis Care and Research, 2016, 68, 1894-1898.	3.4	34
21	Circulating Apoptotic Microparticles in Systemic Lupus Erythematosus Patients Drive the Activation of Dendritic Cell Subsets and Prime Neutrophils for NETosis. Arthritis and Rheumatology, 2016, 68, 462-472.	5.6	131
22	Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis. RMD Open, 2016, 2, e000202.	3.8	43
23	Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It. Journal of Rheumatology, 2016, 43, 1838-1843.	2.0	21
24	Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. Rheumatology, 2016, 55, 2001-2008.	1.9	34
25	An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. Rheumatology, 2016, 55, 2023-2032.	1.9	9
26	Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. BMJ Open, 2016, 6, e012026.	1.9	5
27	What Should Be the Cut Point for Classification Criteria of Studies in Gout? A Conjoint Analysis. Arthritis Care and Research, 2016, 68, 1731-1735.	3.4	4
28	Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated. Journal of Rheumatology, 2016, 43, 150-153.	2.0	25
29	A multidimensional 'path analysis' model of factors explaining fatigue in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 200-6.	0.8	13
30	2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatology, 2015, 67, 2557-2568.	5.6	393
31	Monitoring rheumatoid arthritis using an algorithm based on patient-reported outcome measures: a first step towards personalised healthcare. RMD Open, 2015, 1, e000114.	3.8	14
32	The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes Mellitus. PLoS ONE, 2015, 10, e0132307.	2.5	31
33	Comment on: The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study: reply. Rheumatology, 2015, 54, 1329-1330.	1.9	4
34	Specificity of Systemic Sclerosis Classification Criteria. Journal of Rheumatology, 2015, 42, 2512-2512.	2.0	3
35	Personalizing Treatment Targets in Rheumatoid Arthritis by Using a Simple Prediction Model. Journal of Rheumatology, 2015, 42, 398-404.	2.0	11
36	A Simplified Baseline Prediction Model for Joint Damage Progression in Rheumatoid Arthritis: A Step toward Personalized Medicine. Journal of Rheumatology, 2015, 42, 391-397.	2.0	6

#	ARTICLE	IF	CITATIONS
37	The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2015, 74, 998-1003.	0.9	121
38	Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout. Arthritis Care and Research, 2015, 67, 1304-1315.	3.4	101
39	2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1789-1798.	0.9	545
40	Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Annals of the Rheumatic Diseases, 2015, 74, 1868-1874.	0.9	145
41	The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. Rheumatology, 2015, 54, 609-614.	1.9	47
42	(Bi)Weekly folic acid supplementation might be inferior to a daily folic acid dosing schedule in the prevention of methotrexate-related toxicity in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 767-8.	0.8	1
43	Serum Samples That Have Been Stored Long-Term (>10 Years) Can Be Used as a Suitable Data Source for Developing Cardiovascular Risk Prediction Models in Large Observational Rheumatoid Arthritis Cohorts. BioMed Research International, 2014, 2014, 1-8.	1.9	7
44	Composite Disease Activity and Responder Indices for Psoriatic Arthritis: A Report from the GRAPPA 2013 Meeting on Development of Cutoffs for Both Disease Activity States and Response. Journal of Rheumatology, 2014, 41, 1212-1217.	2.0	85
45	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 2087-2093.	0.9	168
46	Determinants Associated with Work Participation in Patients with Established Rheumatoid Arthritis Taking Tumor Necrosis Factor Inhibitors. Journal of Rheumatology, 2014, 41, 1263-1269.	2.0	6
47	Arthritis of the first metatarsophalangeal joint is not always gout: A prospective cohort study in primary care patients. Joint Bone Spine, 2014, 81, 342-346.	1.6	21
48	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. Journal of Clinical Epidemiology, 2014, 67, 706-714.	5.0	52
49	Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics, 2012, 13, 1087-1094.	1.3	33
50	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	3.4	49
51	Validity of the disease activity score in undifferentiated arthritis. Arthritis Care and Research, 2010, 62, 1392-1398.	3.4	6
52	Outcome measures in inflammatory rheumatic diseases. Arthritis Research and Therapy, 2009, 11, 244.	3.5	44
53	Desirability Scores for Assessing Multiple Outcomes in Systemic Rheumatic Diseases. Communications in Statistics - Theory and Methods, 2009, 38, 3461-3471.	1.0	8
54	The Disease Activity Score and the EULAR Response Criteria. Rheumatic Disease Clinics of North America, 2009, 35, 745-757.	1.9	380

#	Article	IF	Citations
55	Persistent severe fatigue in patients with rheumatoid arthritis. Journal of Clinical Nursing, 2007, 16, 377-383.	3.0	113